These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 18174730)

  • 1. Targeting pituitary tumors.
    Heaney AP
    Horm Res; 2007; 68 Suppl 5():132-6. PubMed ID: 18174730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes.
    Cristina C; Díaz-Torga GS; Goya RG; Kakar SS; Perez-Millán MI; Passos VQ; Giannella-Neto D; Bronstein MD; Becu-Villalobos D
    Mol Cancer; 2007 Jan; 6():4. PubMed ID: 17222350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas.
    Heaney AP; Fernando M; Yong WH; Melmed S
    Nat Med; 2002 Nov; 8(11):1281-7. PubMed ID: 12379847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
    Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
    J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality?
    Tahmatzopoulos A; Kyprianou N
    Prostate; 2004 Apr; 59(1):91-100. PubMed ID: 14991869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rosiglitazone, PPAR-gamma receptor ligand, decreases the viability of rat prolactin-secreting pituitary tumor cells in vitro.
    Gruszka A; Kunert-Radek J; Pawlikowski M
    Neuro Endocrinol Lett; 2005 Feb; 26(1):51-4. PubMed ID: 15726020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Distribution and expression of peroxisome proliferator activated receptor gamma in human pituitary adenomas].
    Ma Y; Xia XW; Su CB; Kong YG
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun; 28(3):375-7. PubMed ID: 16900637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer.
    Hamakawa H; Nakashiro K; Sumida T; Shintani S; Myers JN; Takes RP; Rinaldo A; Ferlito A
    Head Neck; 2008 Jun; 30(6):800-9. PubMed ID: 18429007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxisome proliferator-activated receptor gamma: a novel target for cancer therapeutics?
    Han S; Roman J
    Anticancer Drugs; 2007 Mar; 18(3):237-44. PubMed ID: 17264754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenesis and mutagenesis of pituitary tumors.
    Sonabend AM; Musleh W; Lesniak MS
    Expert Rev Anticancer Ther; 2006 Sep; 6 Suppl 9():S3-14. PubMed ID: 17004855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of peroxisome proliferator-activated receptor activation on gonadotropin transcription and cell mitosis induced by bone morphogenetic proteins in mouse gonadotrope LbetaT2 cells.
    Takeda M; Otsuka F; Otani H; Inagaki K; Miyoshi T; Suzuki J; Mimura Y; Ogura T; Makino H
    J Endocrinol; 2007 Jul; 194(1):87-99. PubMed ID: 17592024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of dopamine receptors in normal and tumoral pituitary corticotropic cells and adrenal cells.
    Boschetti M; Gatto F; Arvigo M; Esposito D; Rebora A; Talco M; Albertelli M; Nazzari E; Goglia U; Minuto F; Ferone D
    Neuroendocrinology; 2010; 92 Suppl 1():17-22. PubMed ID: 20829613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibroblast growth factor 2 and estrogen control the balance of histone 3 modifications targeting MAGE-A3 in pituitary neoplasia.
    Zhu X; Asa SL; Ezzat S
    Clin Cancer Res; 2008 Apr; 14(7):1984-96. PubMed ID: 18381936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting MAPK (Ras/ERK) and PI3K/Akt pathways in pituitary tumorigenesis.
    Cakir M; Grossman AB
    Expert Opin Ther Targets; 2009 Sep; 13(9):1121-34. PubMed ID: 19637976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclooxygenase-2 (COX-2) and epidermal growth factor receptor (EGFR) expression in human pituitary macroadenomas.
    Bloomer CW; Kenyon L; Hammond E; Hyslop T; Andrews DW; Curran WJ; Dicker AP
    Am J Clin Oncol; 2003 Aug; 26(4):S75-80. PubMed ID: 12902861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of the PPAR-γ system in normal and tumoral pituitary corticotropic cells and adrenal cells.
    Mannelli M; Cantini G; Poli G; Mangoni M; Nesi G; Canu L; Rapizzi E; Borgogni E; Ercolino T; Piccini V; Luconi M
    Neuroendocrinology; 2010; 92 Suppl 1():23-7. PubMed ID: 20829614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Key signaling molecules in pituitary tumors.
    Tanase CP; Neagu M; Albulescu R
    Expert Rev Mol Diagn; 2009 Nov; 9(8):859-77. PubMed ID: 19895231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polysialylated-neural cell adhesion molecule expression in rat pituitary transplantable tumors (spontaneous mammotropic transplantable tumor in Wistar-Furth rats) is related to growth rate and malignancy.
    Daniel L; Trouillas J; Renaud W; Chevallier P; Gouvernet J; Rougon G; Figarella-Branger D
    Cancer Res; 2000 Jan; 60(1):80-5. PubMed ID: 10646857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology.
    Ferone D; Gatto F; Arvigo M; Resmini E; Boschetti M; Teti C; Esposito D; Minuto F
    J Mol Endocrinol; 2009 May; 42(5):361-70. PubMed ID: 19141603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.